This week we highlight a study showing promising results that providing high dose vitamin D supplements along with antibiotics could improve treatment outcomes for TB patients. The abstract and additional news coverage are included, as well as, links to other TB R&D news.
The 2012 Millennium Development Report was just released highlighting progress made to date. Great strides have been made in HIV and TB from the year 1990 (see below). The Global Plan to Stop TB issued by the Stop TB Partnership is set within the context of the Millennium Development Goals (MDGs).
The Africa Coalition on Tuberculosis (ACT!) kicked off activities at a week-long planning meeting in June in Tirano, Italy. ACT!’s mission is to value and consolidate the power within communities throughout Africa to end the injustice of TB, a curable disease from which millions of our people suffer and die each year. Albert Makone, Community Representative for the Working Group on New TB Drugs, is a member of ACT!.
Yesterday, efficacy data from the first novel regimen trial (NC001) were published in the Lancet. The results found that the regimen containing PA-824, moxifloxacin, and pyrazinamide, could kill more than 99 percent of patients’ TB bacteria within two weeks and could be more effective than existing treatments. Link to article, press release, and related video are included. Additional links to TB R&D news are also included.
This week it was announced the Janssen Pharmaceuticals, Inc., a pharmaceutical company of Johnson & Johnson, filed a new drug application (NDA) with the U.S. Food and Drug Administration (FDA) for their drug Bedaquiline (a.k.a. TMC-207).
The Stop TB Partnership made two exciting announcements today: 1. US$ 40 million committed to roll-out of Xpert and 2. Dramatic results from TB REACH mHealth project make case for wider implementation.
This week, efficacy data from the recently completed Phase 2 randomized placebo-controlled trial in MDR patients evaluating delamanid with background treatment compared to placebo with background treatment was published yesterday in the New England Journal of Medicine. Delamanid (OPC-67683) is a new agent derived from the nitro-dihydro-imidazooxazole class of compounds that inhibits mycolic acid synthesis. The abstract and overview of news coverage are presented, as well as, additional links to TB R&D news.
For this week’s update, we will highlight three recent articles that look at repurposing and optimizing drugs already on the market or looking at novel targets and drug classes for TB. Additional links to TB R&D news are included.
A briefing and update on tuberculosis (TB), a disease that is curable but still takes the lives of 4,000 people each day and is the number one killer of people living with HIV. Links to video included.
The latest news from the Stop TB Partnership as of April 2012.